BERÁNEK, Michal, Petr KOLÁŘ, Svatava TSCHÖPLOVÁ, Kateřina KAŇKOVÁ and Anna VAŠKŮ. Genetic variations and plasma levels of the Gelatinase A (matrix metalloproteinase-2) and Gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Molecular Vision. 2008, vol. 14, No 1, p. 1114-1121. ISSN 1090-0535.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Genetic variations and plasma levels of the Gelatinase A (matrix metalloproteinase-2) and Gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy
Name in Czech Genetic variations and plasma levels of the Gelatinase A (matrix metalloproteinase-2) and Gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy
Authors BERÁNEK, Michal (203 Czech Republic), Petr KOLÁŘ (203 Czech Republic, belonging to the institution), Svatava TSCHÖPLOVÁ (203 Czech Republic, belonging to the institution), Kateřina KAŇKOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Anna VAŠKŮ (203 Czech Republic, belonging to the institution).
Edition Molecular Vision, 2008, 1090-0535.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30202 Endocrinology and metabolism
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.464
RIV identification code RIV/00216224:14110/08:00024690
Organization unit Faculty of Medicine
UT WoS 000257890500002
Keywords in English retinopathy; MMP; diabetes
Tags Diabetes, MMP, retinopathy
Tags International impact, Reviewed
Changed by Changed by: prof. MUDr. Petr Kolář, Ph.D., učo 63563. Changed: 29/10/2012 10:22.
Abstract
Purpose: The matrix metalloproteinases (MMPs) are postulated to be involved in the development of retinal angiogenesis through the regulation of extracellular matrix. The objective of the present study was to test for a possible association of five single nucleotide polymorphisms (SNPs) in the MMP-2 gene and two polymorphisms in the MMP-9 gene with proliferative diabetic retinopathy (PDR) and to determine their plasma levels. Methods: Genotypes were detected by polymerase chain reactions followed by restriction analyses with specific endonucleases and their frequencies determined in a study comprising three groups of Caucasian subjects (total n=490, diabetics with and without PDR and non-diabetics). The plasma levels of the MMP-2 and -9 proteins were analyzed by ELISA. Results: Neither MMP-2 nor MMP-9 SNPs revealed significant association with PDR in single-locus comparisons; similarly, MMP-2 haplotype frequencies did not differed significantly between groups. Both MMP-2 and MMP-9 plasma levels showed statistically significant differences among the studied groups (p<0.001 and p=0.001, respectively) with highest levels in the PDR group. MMP-2 plasma levels were significantly higher in carriers of either the -1306CC and CT genotypes (p=0.009) or CGCG haplotype (p=0.043). Conclusions: These findings indicate that genotype- and haplotype-specific effects on the MMP-2 gene expression corresponding with its plasma levels may contribute to the susceptibility to PDR.
Abstract (in Czech)
Purpose: The matrix metalloproteinases (MMPs) are postulated to be involved in the development of retinal angiogenesis through the regulation of extracellular matrix. The objective of the present study was to test for a possible association of five single nucleotide polymorphisms (SNPs) in the MMP-2 gene and two polymorphisms in the MMP-9 gene with proliferative diabetic retinopathy (PDR) and to determine their plasma levels. Methods: Genotypes were detected by polymerase chain reactions followed by restriction analyses with specific endonucleases and their frequencies determined in a study comprising three groups of Caucasian subjects (total n=490, diabetics with and without PDR and non-diabetics). The plasma levels of the MMP-2 and -9 proteins were analyzed by ELISA. Results: Neither MMP-2 nor MMP-9 SNPs revealed significant association with PDR in single-locus comparisons; similarly, MMP-2 haplotype frequencies did not differed significantly between groups. Both MMP-2 and MMP-9 plasma levels showed statistically significant differences among the studied groups (p<0.001 and p=0.001, respectively) with highest levels in the PDR group. MMP-2 plasma levels were significantly higher in carriers of either the -1306CC and CT genotypes (p=0.009) or CGCG haplotype (p=0.043). Conclusions: These findings indicate that genotype- and haplotype-specific effects on the MMP-2 gene expression corresponding with its plasma levels may contribute to the susceptibility to PDR.
Links
GP303/05/P523, research and development projectName: Vztah genetických polymorfizmů v kandidátních genech účastnících se procesu angiogeneze k proliferativní retinopatii u diabetes mellitus 2. typu
Investor: Czech Science Foundation, Relationship between genetic variability in candidate genes involved in angiogenesis and proliferative retinopathy in Type 2 diabetes mellitu
PrintDisplayed: 11/9/2024 06:52